AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$INLX

TAGLICH ROBERT purchased $20K of INLX

TAGLICH ROBERT purchased 4,000 shares of INTELLINETICS, INC. (INLX) at $5.00 on 2026-10-06.

Original reporting
SEC EDGAR · TAGLICH ROBERT
Published Oct 7, 2026, 8:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 8:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$INLX
Neutral
high confidence
Mentioned
$INLX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INLXNeutralLow
01

Why it matters

The filing provides a fresh data point on insider sentiment but is unlikely to move the stock materially.

02

Market read

A routine insider purchase with limited trading relevance.

03

What to watch

Potential upcoming clinical milestones not disclosed in the filing.

Relevance 4/10Novelty 4/10Timing: today

Background

Intellinetics, Inc. (INLX) filed a Form 4 reporting a $20K insider purchase.

Company-level read

Ticker impact

$INLXNeutralHigh confidence
Context

SEC Form 4 shows insider Robert Taglich bought 4,000 shares for $20,000, increasing his stake to 459,338 shares.

Expected impact

slight upward pressure as market digests insider buying

Evidence & confidence

The transaction is a primary filing, but the amount is low relative to float, limiting market impact.

Market effects

Sector

Minimal effect on the biotech sector; insider activity is routine.

Regional

No regional impact.

Global

Limited to investors tracking insider activity in small-cap biotech.

Counterpoint

What could challenge this read

The purchase could be a tactical move unrelated to company fundamentals.

Key entities

  • company
    Intellinetics, Inc.

    US-listed biotech company (NASDAQ: INLX).

  • person
    Robert Taglich

    Insider holding a 10% ownership stake.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

INLX insider trading history →

Related articles

$INLXMed

Intellinetics Reports Second Quarter and Six-Month 2026 Results

INTELLINETICS, INC. (INLX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Intellinetics Reports Second Quarter and Six-Month 2026 Results COLUMBUS, OH – August 12, 2026 – Intellinetics, Inc. ( NYSE American: INLX ), a digital transformation solutions provider, announced financial results for the three and six months ended June 30, 2026. 20

SEC EDGAR 8-K
$CTEVLow

ARES MANAGEMENT LLC purchased $2.9M of CTEV (indirect holdings)

ARES MANAGEMENT LLC purchased 115,579 indirectly-held shares of Claritev Corp (CTEV) at an average of $25.40 ($24.42–$26.14, $2.94M total) across 2 trades over 2026-11-09 to 2026-11-10. Filed jointly with ASOF Investment Management LLC (10% owner), Ares Management Holdings L.P. (10% owner), Ares Holdco LLC (10% owner), Ares Management Corp (10% owner), Ares Voting LLC (10% owner), Ares Management GP LLC (10% owner) and Ares Partners Holdco LLC (10% owner).

SEC EDGAR